A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil

Oral treprostinil has recently been shown to delay disease progression in patients with pulmonary arterial hypertension (PAH) in a long-term outcomes study. The potential advantages of an oral form...